<DOC>
	<DOCNO>NCT00151645</DOCNO>
	<brief_summary>Renal cell carcinoma represent today 3 % solid tumor adult . Their bad prognosis due frequency metastasis resistance chemotherapy . Immunotherapy ( interferon-α , interleukin-2 ) show good result important toxicity . In study , evaluate response new therapeutic strategy combine injection patient 's activated lymphocyte classic immunotherapy interferon-α interleukin-2 .</brief_summary>
	<brief_title>Efficacy Activated Lymphocytes Renal Cell Carcinoma .</brief_title>
	<detailed_description>Phase I II trial treatment melanoma renal cell carcinoma already evaluate lymphokine-activated killer cell tumor-infiltrating cell . In metastatic renal cell carcinoma , therapy show complete response low toxicity . In study , evaluate response new therapeutic strategy combine injection patient 's activated lymphocyte classic immunotherapy interferon-α interleukin-2 . A secondary objective improve cell preparation method characterize functionally phenotypically injected cell .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patients age 18 70 year Metastatic renal adenocarcinoma histologically proven Karnofsky performance status ≥ 70 % Life expectation &gt; 3 month At least one target , nonirradiated area Objective response steadystate treatment cytokine Informed write consent Patients present one metastatic site one hepatic metastasis diagnose within last 12 month White blood cell count &lt; 2.5 G/L , Platelet count &lt; 100 G/L Serum creatinine rate &gt; 150 µmol/L Positive serology : hepatitis B , hepatitis C , retrovirus Patient available longterm followup Bellini duct tumor History allograft tumor within five past year Severe cardiovascular , hepatic , renal pulmonary trouble Autoimmune disease Severe infection Pregnancy breastfeeding Corticotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Metastasis</keyword>
	<keyword>Lymphokine activate killer</keyword>
	<keyword>Cell therapy</keyword>
</DOC>